Abstract Background: Suppression of intestinal flora by broad-spectrum antimicrobial agents facilitated risk of colonization or infection with resistant pathogen. We aimed to investigate the changes in bowel carriage of target resistant microorganisms (TRO) among patients treated with three different classes of Pseudomonas-sparing broad-spectrum antimicrobial agents (ertapenem, moxifloxacin and flomoxef) with anaerobic coverage. Risk factors for developing colonization of TRO were also analyzed. Methods: We prospectively enrolled the adult hospitalized patients (>20 years old) who were indicated for at least 7-day course with either of ertapenem, moxifloxacin or flomoxef. Rectal swabs were performed for the patients who received at least 1-day course of study antibiotics during the treatment duration. The TROs included Pseudomonas aeruginosa, Enterobacteriaceae, and Acinetobacter baumannii. MacConkey agars with study antibiotics were used to isolate the TROs and evaluate the antimicrobial resistance. Results: The mean age of our study population was 61.6 years, and 58.8% were males. The rates of rectal colonization for Pseudomonas aeruginosa was similar among the study medications (ertapenem 13.2%, flomoxef 20%, moxifloxacin 14.3%, p Z 0.809). Compared with ertapenem, flomoxef (odds ratio [OR], 4.30; 95% confidence interval [95% CI], 1.28e14.48, p Z 0.019) and moxifloxacin (OR, 6.95; 95% CI, 1.36e35.52, p Z 0.019) had higher risk for colonization of ertapenem-resistant Escherichia coli colonization.
Introduction
The normal flora of the gastrointestinal tract provides native barrier to colonization by antimicrobial resistant bacteria and fungi. 1 Suppression of intestinal anaerobic flora facilitates colonization and infection with pathogenic aerobic bacteria. 2 For example, the risk of colonization or infection with vancomycin-resistant enterococci (VRE) has been associated with the use of glycopeptides, 3, 4 third generation cephalosporins, 5, 6 and antibiotics with antianaerobic activity. 7 In contrast, the effects of the broadspectrum antibacterial agents on colonization with resistant Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter baumannii had less been investigated. 8 Gastrointestinal tract is the most common habitat of bacteria. It has been estimated to 10 11À12 colony forming units habit in the colon, more than 99% are anaerobes. 9 Colonization of potential antimicrobial resistant pathogens could be selected under the pressure of using broadspectrum antimicrobial agents. In vivo studies and an epidemiological study revealed colonization of carbapenemresistant Enterobacteriaceae could developed after using broad-spectrum antibiotics, such as carbapenems. Among the patients who received transrectal biopsy of the prostate, Escherichia coli was the most common pathogens. 13 Therefore, we focus on the ertapenem-resistant E. coli under the usage of broad spectrum antibiotics. In this study, the effect of three P. aeruginosa-sparing board spectrum antimicrobial agents (ertapenem, moxifloxacin and flomoxef) commonly used for intra-abdominal infections on the changes of bowel colonization with target resistant organisms (TROs) were accessed by serial cultures collected from rectal swabs. In addition, risk factors of bowel colonization of TRO were assessed.
Materials and methods

Study design
This is a prospective observational study of serial anal swabs for cultures among patients who were treated with three targeted broad-spectrum Pseudomonas-sparing antimicrobial agents (ertapenem, moxifloxacin and flomoxef) during the period of April 2008 to December 2009 at National Taiwan University Hospital. The inclusion criteria included all of the followings: (1) male or female patients over 20 years of age, (2) patients who were estimated for an at least 5 days of antimicrobial treatment with either of targeted antimicrobial therapy (ertapenem, moxifloxacin or flomoxef), (3) patients could receive anal swab culture within 72 h of initiating targeted antimicrobial therapy. The choices of these therapeutic regimens were decided by their attending physicians based on the clinical practice. Patients with the following condition were excluded: (1) patients received concomitant other antimicrobial agents in addition to these targeted antimicrobial medication or change to other antimicrobial agents, (2) patients who required more than 4-week duration of antimicrobial agent therapy, (3) patients had concomitant infections that might interfere with the evaluation of the response to studied medications, (4) patients underwent unscheduled surgery or requiring laparotomy for perforated or ruptured bowels or other acute conditions, (5) patients who were previously documented positive for TRO colonization and/or infection before or had received intravenous antimicrobial therapy within 1 year.
Data collection
Patients who met the inclusion criteria and had signed informed consents to participate the study were enrolled. A standardized case record form was used to collect information on demographic and clinical characteristics (age, sex, comorbidities), sites of infections, antimicrobial treatment course, baseline hemogram and blood biochemistry, clinical outcomes (septic shock, mortality), and adverse effects of antibiotics. Rectal swabs were performed within 72 h (early follow-up assessment) and the end of targeted antimicrobial therapy.
Laboratory investigations
Rectal Swabs were performed as following procedure: (1) insert the swab into the rectum as if taking a rectal temperature, (2) place one swab in a tube containing bufferedglycerol-saline (BGS), (3) cut or break the swab to fit in to the tube and screw the cap on tightly, (4) store the BGS tube at 4 C and make sure the swab is moistened with the transport media. If the patient was withdrawn from the study prior to the early follow-up assessment, collected rectal swabs were discarded from the study.
Target resistant organisms (TROs)
The Target Resistant Organisms (TROs) of interest include ertapenem-resistant Enterobacteriaceae, extendedspectrum b-lactamases-(ESBL-) or APC b-lactamases-producing Enterobacteriaceae, P. aeruginosa, and A. baumannii. The methods of TRO isolation were performed according to the CLSI standards.
14 The swabs were cultures on the following selective media plates to isolate gramnegative bacilli, such as MacConkey agar with ertapenem 0.5 mg/ml; MacConkey agar with ceftriaxone 1 mg/ml, MacConkey agar with moxifloxacin 1 mg/ml and MacConkey agar with flomoxef 1 mg/ml. All swabs were only applied to selective agar to isolate the resistant microorganisms.
Ethics statement
This research conformed to the Helsinki Declaration and local legislation, and was approved by the Institutional Review Board National Taiwan University Hospital Research Ethics Committee (NTUH 200712004R). Written informed consent from the participants were performed of each patient in this study.
Statistical analysis
We used Fisher exact test or Chi square test for categorical variables among the three groups of patients (ertapenem, flomoxef, and moxifloxacin), and utilized unbalanced ANOVA analysis for the examination of continuous variables. We included the variables with a p-value <0.05 in the univariate analysis such as age, lung infection, urinary tract infection, underlying hepatobiliary diseases, and underlying endocrine diseases, and variables that were of biological significance such as sex and antibiotics treatment duration in the multivariate logistic regression models. The ertapenem group was used as the reference group in the logistic regression model. A p value of <0.05 was considered statistically significant. The confidence interval was set at 95%. The analysis was conducted using the statistical package SAS 9.3 (SAS Institute Inc., Cary, North Carolina, USA).
Results
During the study period, 97 patients who received study antibiotics were enrolled. There were 38, 45, and 14 patients in the ertapenem, flomoxef, and moxifloxacin groups, respectively. The mean age of the moxifloxacin group was significantly younger (51.1 AE 12.5 years) than those of ertapenem group and flomoxef group (64.0 AE 19.4 years and 62.7 AE 13.8 years, respectively, p Z 0.034).
The overall clinical characteristics of the 97 study patients were shown in Table 1 . Compared with ertapenem group and moxifloxacin group, the flomoxef group had higher proportion of patients who had hepatobiliary disease (66.7% versus 31.6% and 35.7%, p Z 0.004) and suffered from hepatobiliary infection (44.4% versus 23.7% and 14.3%, p Z 0.039). The ertapenem group had higher proportion of urinary tract infection (23.7% versus 4.4% and 0%, p Z 0.013) and the moxifloxacin group had higher proportion of pulmonary infections (42.9% versus 15.8% and 11.1%, p Z 0.036). The treatment duration and clinical responses were revealed by Table 2 . The mean duration of therapy was 6.9 days for all the study patients, and there was no significant difference of treatment duration among the three study groups. The disease severity (septic shock, intensive care unit admission, acute renal failure, and 30-day mortality) and side effects profiles (skin rash, abdominal fullness, and decreased urine output) were also similar among the three study groups.
The microbiological profiles of anal colonization were shown in Table 3 . The median duration from initiation of antimicrobial therapy to collection of rectal swab cultures was 3 days (min 1 day, max 14 days), and there was no significant difference among the three study groups. For P. aeruginosa, the overall colonization rate was 16.5%, and the proportion of colonization was similar among the three groups (13.2% versus 20% versus 14.3%, p Z 0.809). The colonization rates of non-fermentative Gram negative bacilli (NFGNB) were similar among the three study groups. The overall colonization rate of Enterobacteriaceae was 59.8%. However, the colonization rate was borderline significant lower in the ertapenem group (44.7% versus 71.1% and 64.3%, p Z 0.052). Compared with the other two groups, ertapenem group had lower rates of E. coli colonization (21.1% versus 53.3% and 57.1%, p Z 0.004) but higher rates of S. marcescens colonization (10.5% versus 0% and 0%, p Z 0.049).
The colonization rates of resistant Gram negative bacteria were shown in Table 4 . The proportion of ertapenemresistant E. coli colonization was significantly lower of the ertapenem group (13.2% versus 44.4% and 50%, p Z 0.002).
To do a sensitivity test, the ertapenem group had a significant lower colonization rate of ertapenem resistant E. coli than the flomoxef group (ertapenem versus flomoxef, 13.2% versus 44.4%, p Z 0.002) and the moxifloxacin group (ertapenem versus moxifloxacin, 13.2% versus 50%, p Z 0.01). The colonization rates of flomoxef-and moxifloxacin-resistant E. coli were also significantly lower in the ertapenem group. The proportions of resistant Klebsiella pneumoniae colonization were similar among the three study groups.
By multivariate logistic regression analysis to clarify the risk factors for colonization of ertapenem-resistant E. coli, we found that use of flomoxef or moxifloxacin would have a significantly higher odds ratio than use of ertapenem for colonization ( Table 5 ). The adjusted odds ratios were 4.30 and 6.95 for flomoxef and moxifloxacin, respectively. The age, antibiotics treatment duration, and other possible confounding underlying medical diseases did not pose a significant effect on the anal colonization of ertapenemresistant E. coli.
Discussion
In this study of anal colonization of Gram-negative bacteria after using pseudomonas-sparing broad spectrum antibiotics, it revealed 16.5% colonization rate of P. aeruginosa from the anal swab culture results among all the study patients. Previous reports revealed the colonization rate of P. aeruginosa were about 6% for healthy young adults and between 3% and 24% for hospitalized patients. 15, 16 Our study is compatible with these results. The bowel source of P. aeruginosa may also plays some roles for nosocomial infections. 17 Therefore, the rectal colonization of P. aeruginosa was not significantly higher at our study subjects who receiving the broad spectrum pseudomonas-sparing antibiotics. From the experience of a 344-bed community teaching hospital, ertapenem was effective in their antimicrobial stewardship program after being added to the formulary and may improve the P. aeruginosa antimicrobial susceptibility to imipenem by decreasing the unnecessary usage and selective pressure of antipseudomonal agents. 18 We found that the patients who underwent the use of ertapenem had a significant lower anal colonization proportion of ertapenem-resistant E. coli than the patients who received flomoxef and moxifloxacin. The rectal colonization rate of ertapenem-nonsusceptible E. coli was about 5% in hospitalized patients. 19 A previous bacteriological study revealed that the acquisition of the plasmidmediated blaDHA-1 gene has led to flomoxef resistance in Lkp14 strain of K. pneumoniae after flomoxef exposure. Furthermore, the concomitant depletion of outer membrane protein (OmpK36) caused a collateral effect of ertapenem resistance and diminished susceptibilities to imipenem and meropenem. 20 The mechanism of collateral damage for flomoxef on carbapenem may explain the high proportion (44.4%) of ertapenem-resistant E. coli colonization in our study. The previous usage of quinolones had been noted as a risk factor for infection with ESBLproducing Klebsiella species and E. coli in nursing homes by a caseecontrol study. 21, 22 Moreover, in-hospital consumption of fluoroquinolones was significantly correlated with carbapenem resistance in E. coli by the analysis of the data from in the US military health system. 23 Comparing the pharmacokinetics of the three antibiotics, ertapenem and moxifloxacin had a more steady plasma concentration and longer half life than flomoxef.
24e26 A lower concentration below the minimum inhibitory concentration (MIC) can induce and select more resistant pathogens. Thus, it could affect the total colonization of resistant Gram negative bacteria, including E. coli. Due to a high fluoroquinolone resistance rate about 30% of E. coli in Taiwan, 27 it could make a lower rate of rectal colonization for E. coli in the ertapenem group.
Our study was under a prospective design. Therefore, we collected the anal swab specimens during the usage of study antibiotics under a standard protocol. We used MacConkey agar with a fixed concentration of tested antibiotics, and then the susceptibility of bacteria could be interpreted clearly by an all-or-none culture results. The susceptible minimum inhibitory concentration (MIC) breakpoint of Enterobacteriaceae for ertapenem was cut at 0.5 mg/ml, which was set according to the M100-S24 criteria published by Clinical and Laboratory Standards Institute (CLSI).
14 If the MIC equals 1.0 mg/ml, the cultured strain will be defined as intermediate for ertapenem. Therefore, some parts of the patients in our ertapenem-resistant E. coli group may belong to the intermediate susceptibility.
There were some limitations of our study. First, we included a relative small numbers of study patients and the unbalanced subject numbers between the three study antibiotics. The small case numbers of the moxifloxacin group may lead to some selection bias for the colonization status of the group. Second, we did not test the drug susceptibility of other anti-pseudomonal carbapenems, such as imipenem or meropenem, in this study. Therefore, we cannot reveal the whole picture of the carbapenem resistance in our isolates. The discordance of drug susceptibility for carbapenems had been notified before. 28 Third, the genotype assay for carbapenemase, including NDM-1 and KPC, was not checked here. Then we could not know the exact mechanisms for the ertapenem resistance. Fourth, the lower colonization rate of ertapenem-resistant E. coli may result from the uneven distribution of total E. coli colonization number among three groups. If we only focused on the proportion of the resistant E. coli and K. pneumoniae isolates number divided by the total number of isolated E. coli and K. pneumoniae, respectively, it would not reveal a statistical significance for the lower colonization of ertapenem resistant E. coli in the ertapenem group (Table  6 ). Finally, we did not have the complete culture results before using and after ceasing the study antibiotics. Thus, we were unable to show the baseline colonization of the anal swabs before starting the antibiotics and clarify the flora changes after the course of using antibiotics.
In conclusion, the broad spectrum pseudomonas-sparing antibiotics may increase the anal colonization rate of ertapenem resistant E. coli. Use of flomoxef or moxifloxacin can have a significantly higher risk of ertapenem resistant E. coli colonization than administering ertapenem. Thus, the collateral damage for carbapenem resistance should be noticed while we use fluoroquinolones or oxacephams. The antibiotics had significant effects on the colonization flora of the patients.
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